BWP
REGN icon

Baldwin Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Baldwin Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$3.15K – 830
2024
Q3 		$3.15K Buy
+3
New +$3.34K ﹤0.01% 913
2023
Q2 		– Sell
-49
Closed -$40.3K – 791
2023
Q1 		$40.3K Sell
49
-110
-69% -$83K ﹤0.01% 440
2022
Q4 		$115K Sell
159
-195
-55% -$144K 0.01% 294
2022
Q3 		$244K Sell
354
-26
-7% -$16.4K 0.03% 154
2022
Q2 		$225K Sell
380
-567
-60% -$369K 0.03% 167
2022
Q1 		$661K Sell
947
-12,661
-93% -$8.01M 0.07% 96
2021
Q4 		$8.59M Buy
13,608
+791
+6% +$486K 0.86% 34
2021
Q3 		$7.76M Buy
12,817
+625
+5% +$388K 0.86% 36
2021
Q2 		$6.81M Buy
12,192
+462
+4% +$234K 0.74% 39
2021
Q1 		$5.55M Buy
11,730
+395
+3% +$192K 0.66% 45
2020
Q4 		$5.48M Buy
11,335
+3,251
+40% +$1.75M 0.69% 43
2020
Q3 		$4.53M Buy
8,084
+2,036
+34% +$1.23M 0.62% 47
2020
Q2 		$3.77M Buy
6,048
+448
+8% +$254K 0.55% 51
2020
Q1 		$2.73M Buy
+5,600
New +$2.31M 0.48% 54

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baldwin Wealth Partners's REGN Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 3 shares — an estimated $3.15K sold.

Baldwin Wealth Partners first reported a position in REGN in Q1 2020 and held it in 14 quarters. The position peaked at $8.59M in Q4 2021. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Baldwin Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Baldwin Wealth Partners sold 3 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $3.15K.
  • Baldwin Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Baldwin Wealth Partners's Regeneron Pharmaceuticals position peaked at $8.59M in Q4 2021.
  • 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.